Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Mult Scler ; 26(13): 1801-1803, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-32031458

RESUMO

Teriflunomide is an oral monotherapy used to treat relapsing multiple sclerosis. Although teriflunomide may be associated with gastrointestinal symptoms, these events are mild and self-limiting. We present a 39-year-old female who developed severe diarrhea and lost 20 pounds within 3 weeks of starting teriflunomide. Despite discontinuing teriflunomide and undergoing cholestyramine washout, her symptoms persisted. Celiac disease on genetic testing was positive, but no anti-transglutaminase and anti-endomysial antibodies were detected. She underwent colonoscopy and biopsy was consistent with lymphocytic colitis. Remission was achieved within days of starting budenoside. Our case describes a rare, but serious, gastrointestinal adverse event of teriflunomide.


Assuntos
Colite Linfocítica , Esclerose Múltipla Recidivante-Remitente , Esclerose Múltipla , Adulto , Crotonatos/efeitos adversos , Feminino , Humanos , Hidroxibutiratos , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Nitrilas , Toluidinas
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa